[redacted]

Lista de terapias

Frase de búsqueda: axicabtagene ciloleucel

A continuación, encontrarás una lista de sustancias activas registradas por la Agencia Médica Europea (EMA) en los últimos 15 años y recomendadas por la Sociedad Europea de Oncología Médica (ESMO), así como el estatus de su financiación con fondos públicos en tu país.

Linfomas no Hodgkin

Axicabtagene ciloleucel	Axicabtagene ciloleucel is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. Axicabtagene ciloleucel is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. Axicabtagene ciloleucel is indicated for the treatment of adult patients with r/r follicular lymphoma (FL) after three or more lines of systemic therapy.	RESTRICCIONES ESMO